Hepatitis C Clinic

The Hepatitis C Treatment Centerlogo-1

The Hepatitis C Treatment Center brings together our dedicated, caring professionals to provide patients with the latest evaluation, treatment methods and medications for the management and cure of Hepatitis C Infection. We’re dedicated to helping you change your future.


Research

Infectious Diseases Associates of Central Virginia is very involved in clinical trials related to a variety of areas. Participation as a clinical trial site has included studies related to vaccines, HIV, hepatitis C, Clostridium Difficile, bacterial skin/wound infections, and other infectious diseases.

Currently Enrolling
A study to evaluate the quality of life for HIV-infected patients switched to raltegravir versus other Antiretroviral Regimens.
Sponsor: Merck

A randomized, modified double-blind, placebo-controlled, multi-center phase 3 trial of efficacy, immunogenicity, and safety study of clostridium difficile vaccine in subjects at risk for C. difficile Infection.
Sponsor: Sanofi Pasteur

A Phase 2 study in which ACH0143102, sovaprevir and ribavirin administered in combination for 12 weeks to subjects with GT1 chronic hepatitis infection, regardless of HCV subtype or IL28B genotype status.
Sponsor: Achillion Pharmaceuticals, Inc.

August 1st Enrollment
Phase 2 & 3 Randomized, Open-label study to evaluate the safety and efficacy of HIV Treatment co-administered with Hepatitis C Treatment in Adults with Genotype 1 Hep C Virus and HIV Type 1 virus.

Phase 111b, Randomized, open label study for HIV-1 infected Treatment Naïve Women ages 18 and up. This study will evaluate the safety and efficacy of single tablet, Dolutegravir/Abacavir/Lamivudine regimen dosed once daily compared to daily regimen of Atazanavir, Ritonavir administered with the fixed dose combination tablet of Tenofovir/Emtricitabine.

Enrollment On Hold
Phase 1b, open-label, pilot study to evaluate the safety, tolerability and antiviral activity of oral ACH-0143102 administered in combination with ribavirin for 12 weeks in treatment naïve subjects with chronic hepatitis C virus infection genotype 1b.
Sponsor: Achillion Pharmaceuticals, Inc. & Duke Clinical Research Institute

Randomized, double-blinded, active-controlled study of CB-183,315 in patients with clostridium difficile associated diarrhea.
Sponsor: Cubist Pharmaceuticals, Inc.

International, multicenter, prospective observational study of the safety of maraviroc used with optimized background therapy in treatment-experienced HIV-1 infected patients.
Sponsor: ViiV Healthcare LTD

Enrollment Complete
Randomized, multicenter, open-label study to compare the efficacy and safety of simplifying from a regimen of boosted reyataz to a regimen of unboosted reyataz.
Sponsor: ViiV Healthcare & GlaxoSmithKline

A study to define treatment duration compliance rates as well as to evaluate the impact of educational programs involving patients with hepatitis C.
Sponsor: Chronic Liver Disease Foundation

Our research staff consisting of physicians, nurse practitioner and clinical coordinators is dedicated to research and strive to be the best clinical trial site for the sponsors and pharmaceutical companies conducting clinical trials.


External Content Disclaimer

*Please note that pages of this site may be linked to other websites, which may have different terms of use and privacy practices than Privia Medical Group. Privia does not own, control, manage, supervise, direct, or otherwise have involvement in such other websites or the content of such websites. Privia is not responsible for the content of any linked websites. Privia is not acting as an agent for these websites, nor does Privia endorse or guarantee, in any way, their websites, content, or products. Privia makes no representation or warranty regarding the accuracy of information contained in linked websites, takes no responsibility for the use of copyrighted or otherwise protected materials on such linked websites, and has no control over the privacy practices or use of user information at such linked websites.